Publications
Print PDF
AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance
May 25, 2021
Angus Liu
FiercePharma

Axinn partner Jeny Maier’s commentary was included in the FiercePharma article, "AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance." 

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.